The Food and Drug Administration’s vaccine advisory panel has approved Moderna’s new flu vaccine, known as mFlusiva or mRNA-1010, for adults ages 50 to 64 and those 65 years and older. Both approvals were secured by overwhelming votes of 9-0.
During a daylong meeting, panelists reviewed the vaccine’s efficacy and safety data, existing influenza vaccination options, and the current U.S. flu landscape. Presenters emphasized that mRNA technology could enable faster production cycles to better align annual vaccines with circulating strains.
Rituparna Das, M.D., Ph.D., Senior Vice President of Clinical Development in Infectious and Rare Diseases at Moderna, stated: “Current influenza vaccine technologies can be affected by the long interval between strain selection and vaccination. By directly encoding the selected antigen sequence, avoiding egg adaptation and supporting a more flexible manufacturing timeline, mRNA-1010 has the potential to address important limitations of current influenza vaccines and improve protection in a population that continues to experience substantial influenza disease burden.”
Brownstone Institute President Jeffrey Tucker characterized the approval as driven by “profits.” Moderna is not alone among COVID-19 vaccine manufacturers to receive recent regulatory approvals, with the CDC awarding Pfizer $1.24 billion for its COVID-19 jabs.
FDA vaccine reviewer Dr. Timothy Brennan suggested the agency might approve the vaccine for older adults ahead of the coming flu season, despite needing additional safety data for frail seniors or individuals with weak immune systems.
If approved, Moderna plans a study involving 400,000 people aged 65 and older, with half receiving mRNA-1010 and the rest a standard senior flu vaccine. The trial will be repeated across two flu seasons.
Moderna’s data showed no major safety concerns but reported temporary reactions including injection-site pain, fever, headache, tiredness and aches—reactions more frequent than with traditional flu shots. The FDA noted these are typical of mRNA vaccines.
Dr. Hayley Gans, a Stanford Medicine pediatrician and FDA adviser, explained that such reactions signal an active immune response and stressed the importance of communicating this to vaccine recipients.
Earlier this year, Moderna’s data was at the center of a public dispute when a then-top FDA official blocked the company’s application for its first mRNA flu shot. Dr. Vinay Prasad, the embattled vaccine chief, stated that Moderna should have compared its shot to a high-dose flu vaccine recommended for seniors rather than a standard-dose brand. This incident occurred under Health Secretary Robert F. Kennedy Jr.’s leadership.